Lv1
20 积分 2021-05-06 加入
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
26天前
已完结
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
2个月前
已完结
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)
3个月前
已完结
LPA 1 ‐induced cytoskeleton reorganization drives fibrosis through CTGF‐dependent fibroblast proliferation
3个月前
已完结
[Chinese expert consensus on multidisciplinary discussion of interstitial lung disease]
5个月前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
6个月前
已完结
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
8个月前
已完结
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
8个月前
已完结
Effects of lysophosphatidic acid receptor 1 (LPA1) antagonism on biomarkers in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF): data from a randomized phase 2 trial with BMS-986278
9个月前
已关闭
《成人特发性肺纤维化(更新)和进展性肺纤维化:ATS/ERS/JRS/ALAT临床实践指南(2022版)》解读(一):进展性肺纤维化识别与治疗
9个月前
已完结
皖公网安备34019202002308
